1. Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells
- Author
-
Jian Hou, Fengxiang Yan, Bin Wang, Lin Liu, Hong Guan, Y. F. Chen, Shuang Geng, Yechun Pei, and Xiaorong An
- Subjects
CD4-Positive T-Lymphocytes ,Allergy ,Immunology ,Population ,medicine.disease_cause ,T-Lymphocytes, Regulatory ,Allergic inflammation ,Mice ,Allergen ,Immune system ,Fel d 1 ,Vaccines, DNA ,medicine ,Animals ,Immunology and Allergy ,education ,Glycoproteins ,Rhinitis ,Pharmacology ,Mice, Inbred BALB C ,education.field_of_study ,biology ,Vaccination ,Interleukin-2 Receptor alpha Subunit ,FOXP3 ,Forkhead Transcription Factors ,medicine.disease ,Asthma ,Disease Models, Animal ,Treatment Outcome ,Cats ,biology.protein ,Female ,Research Paper - Abstract
Pet allergens are major causes for asthma and allergic rhinitis. Fel d 1 protein, a key pet allergen from domestic cat, can sensitize host and trigger asthma attack. In this study, we report that co-immunization with recombinant Fel d 1 protein (rFel d 1) plus plasmid DNA that contains Fe1 d 1 gene was effective in preventing and treating the natural Fel d 1 (nFel d 1) induced allergic airway inflammation in mice. A population of T regulatory cells (iTreg) exhibiting a CD4+CD25-Foxp3+ phenotype and expressing IL-10 and TGF-β was induced by this co-immunization strategy. Furthermore, after adoptive transfers of the iTreg cells, mice that were pre-sensitized and challenged with nFel d 1 exhibited less signs of allergic inflammation, AHR and a reduced allergic immune response. These data indicate that co-immunization with DNA and protein mixture vaccine may be an effective treatment for cat allergy.
- Published
- 2013
- Full Text
- View/download PDF